We hypothesise that cathepsin L2 protects mainly through the following mechanisms: First, It likely inhibits Ang II activity through the AKT/GSK-3 beta pathway, improving cardiac remodeling and reducing the incidence of arrhythmias in AF (Lutgens et al., 2007). Here, CTSV is linked to atrial fibrillation.